NGS Group (NGS) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
6 Aug, 2026Executive summary
Improved market conditions for Nurse & Doc Partner and increased market share for Human Capital led to significantly better results year-over-year.
EBITA for Q2 rose to 3.1 MSEK from 0.1 MSEK, with a margin of 4.4% compared to 0.1% last year.
Net profit for Q2 reached 2.3 MSEK, up from a loss of -0.5 MSEK in the prior year.
Human Capital became the fifth largest recruitment company among Almega-Kompetensföretagen members, up from twentieth two years ago.
Ongoing internal efficiency improvements, including AI-driven processes, contributed to profitability.
Financial highlights
Q2 net revenue: 71.4 MSEK (down 0.4% year-over-year); H1 net revenue: 136.8 MSEK (down 7.4%).
Q2 EBITA: 3.1 MSEK (0.1 MSEK last year); H1 EBITA: 4.8 MSEK (0.0 MSEK last year).
Q2 net profit: 2.3 MSEK (-0.5 MSEK last year); H1 net profit: 4.3 MSEK (-1.4 MSEK last year).
Q2 operating cash flow: 3.2 MSEK (2.4 MSEK last year); H1 operating cash flow: 7.3 MSEK (-7.8 MSEK last year).
Q2 EPS: 0.09 SEK (-0.02 SEK last year); H1 EPS: 0.17 SEK (-0.05 SEK last year).
Outlook and guidance
Strategic initiatives focus on digitalization, offering development, structural capital, and marketing.
Financial targets: 10% organic and acquired revenue growth over time, EBITA margin of 4%, dividend payout of 40-50% of net profit, and net debt/equity ratio max 50%.
Latest events from NGS Group
- EBITA turned positive and net income improved despite a 14% sales drop, driven by cost control.NGS
Q1 2026 - EBITA turned positive in 2025, but goodwill write-down led to a net loss and no dividend.NGS
Q4 2025 - Q3 sales dropped 18% but EBITA improved; new CEO and Human Capital brand launched.NGS
Q3 2025 - EBITA returned to positive in Q2 2025 amid revenue decline and challenging market conditions.NGS
Q2 2025 - Q3 sales dropped 27% but profitability and equity ratio improved amid market challenges.NGS
Q3 2024 - Sharp revenue decline and heavy losses in H1 2024; cost cuts and new deals target recovery.NGS
Q2 2024 - EBITA improved despite a 20% sales drop, driven by cost control and business divestment.NGS
Q1 2025 - Q4 EBITA returned to profit despite lower sales, driven by cost control and segment focus.NGS
Q4 2024